Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pembrolizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pembrolizumab Monotherapy | ACTIVE_COMPARATOR | Participants will be administered with pembrolizumab as monotherapy in a fixed dose. |
| Dostarlimab Monotherapy | EXPERIMENTAL | Participants will be administered with dostarlimab as monotherapy in a fixed dose. |
| Substudy 1A | EXPERIMENTAL | Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose A). |
| Substudy 1B | EXPERIMENTAL | Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose B). |
| Substudy 1C | EXPERIMENTAL | Participants will be administered with dostarlimab in a fixed dose followed by belrestotug in a fixed dose (Dose C). |
| Substudy 2A | EXPERIMENTAL | Participants will be administered with dostarlimab, fixed dose belrestotug, and fixed dose nelistotug |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab | DRUG | Pembrolizumab will be administered. |
| Dostarlimab | DRUG | Dostarlimab will be administered |
| Belrestotug | DRUG | Belrestotug will be administered. |
| Nelistotug | DRUG | Nelistotug will be administered. |
Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced unresectable NSCLC not eligible for curative surgery and/or definitive radiotherapy with or without chemotherapy or metastatic NSCLC (squamous or non squamous) * No prior systemic therapy for their locally...
Pembrolizumab is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer. It is currently in Phase 2 clinical development, with an active trial evaluating it in previously untreated, advanced or metastatic Non-Small Cell Lung Cancer. Pembrolizumab is not yet approved for this indication.
Pembrolizumab targets PDCD1, also known as programmed cell death protein 1, and acts as an inhibitor of this target. By inhibiting PDCD1, Pembrolizumab is designed to modulate the immune response in the context of Non-Small Cell Lung Cancer. This mechanism is being investigated in ongoing clinical trials.
Pembrolizumab is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. GSK is conducting clinical trials to evaluate Pembrolizumab for the treatment of Non-Small Cell Lung Cancer, with the drug currently in Phase 2 development.
Pembrolizumab is currently in Phase 2 clinical development for Non-Small Cell Lung Cancer. It is an investigational drug and has not received FDA approval. The most advanced trial is a Phase 2 platform study, while another early-stage trial has been terminated.
Pembrolizumab is being studied in two clinical trials. The primary trial, NCT05565378, is a Phase 2 platform study of novel immunotherapy combinations in previously untreated, advanced or metastatic Non-Small Cell Lung Cancer, with 351 participants enrolled. A second trial, NCT06405230, was a Phase 1 study that has been terminated.
No, Pembrolizumab is not the same as Keytruda. Pembrolizumab is a small molecule inhibitor of PDCD1 being developed by GSK plc, while Keytruda is a different drug. Pembrolizumab is currently in Phase 2 clinical trials for Non-Small Cell Lung Cancer and is not FDA approved.